{"links":{"html":"https://www.erudio.com/reports/epcore-dlbcl-1-nct04628494","json":"https://www.erudio.com/reports/epcore-dlbcl-1-nct04628494.json","markdown":"https://www.erudio.com/reports/epcore-dlbcl-1-nct04628494.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"epcore-dlbcl-1-04628494"}},"request":"https://www.erudio.com/contact?report=epcore-dlbcl-1-04628494"},"offer":{"cited_commentary_sources":19,"verified_hcp_statements":113,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":8,"optional":true,"price_per_verified_person_usd":15,"price_usd":120,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"epcore-dlbcl-1-nct04628494"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=epcore-dlbcl-1-04628494","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/epcore-dlbcl-1-nct04628494","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-31T00:33:02.443174Z","notify_subscribers":false,"status":"corrected","summary":"Corrected to match the delivered report: the limitations; the sample findings; the report description."},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":14,"no_commentary_found":0},"aspects":[{"claim_count":26,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":10,"title":"Primary endpoint: Overall Survival (OS)"},{"claim_count":15,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":8,"title":"Secondary endpoints"},{"claim_count":10,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":7,"title":"Population and setting"},{"claim_count":19,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":8,"title":"The comparison"},{"claim_count":9,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":4,"title":"Safety and tolerability"},{"claim_count":13,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":6,"title":"Design and conduct"},{"claim_count":9,"coverage":"discussed","id":"A1","source_count":4,"title":"CAR-T/transplant positioning and changing eligibility"},{"claim_count":17,"coverage":"discussed","id":"A2","source_count":4,"title":"Conditional monotherapy preference and combination alternatives"},{"claim_count":6,"coverage":"discussed","id":"A3","source_count":3,"title":"Cross-trial interpretation, comparator strength and information value"},{"claim_count":14,"coverage":"discussed","id":"A4","source_count":3,"title":"Outpatient delivery, infection prevention and supportive care"},{"claim_count":11,"coverage":"discussed","id":"A5","source_count":3,"title":"EPCORE NHL-1 and earlier bispecific evidence informing the R/R DLBCL choice"},{"claim_count":4,"coverage":"discussed","id":"A6","source_count":1,"title":"Sequencing, CD20 reassessment, cure and long-term uncertainty"},{"claim_count":11,"coverage":"discussed","id":"A7","source_count":5,"title":"Confirmatory evidence, regulatory interpretation and endpoint communication"},{"claim_count":5,"coverage":"discussed","id":"A8","source_count":4,"title":"Enrollment feasibility and nonclinical expectations"}],"counts":{"cited_sources":19,"claims_by_expression_type":{"comparison":9,"experience":2,"interpretation":26,"opinion":21,"question":1,"restatement":20,"uncertainty":10,"unspecified":24},"claims_by_kind":{"interpretation":1,"source_observation":112},"clinician_statements":39,"evidence_units":46,"findings":10,"organisational_accounts":3,"people_cited":13,"people_identity_verified":8,"people_total":13,"screened_sources":63,"verified_claims":113},"findings_index":[{"id":"F1","structure":{"claims":28,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":12,"views":14},"has_counterview":true,"limitations":4,"links":{"context":0,"support":34},"ma_question":true,"named_voices":6,"passages":14,"sources":9,"sources_by_kind":{"commentary":5,"media":4}},"title":"Survival and infection risk constrain the interpretation of success"},{"id":"F2","structure":{"claims":16,"claims_by_group":{"comparisons":2,"experience":0,"questions":2,"restated":5,"views":7},"has_counterview":false,"limitations":3,"links":{"context":1,"support":19},"ma_question":true,"named_voices":5,"passages":13,"sources":7,"sources_by_kind":{"commentary":3,"media":4}},"title":"The perceived efficacy signal is response durability, not the median PFS difference"},{"id":"F3","structure":{"claims":8,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":0,"views":6},"has_counterview":true,"limitations":3,"links":{"context":1,"support":8},"ma_question":true,"named_voices":2,"passages":3,"sources":3,"sources_by_kind":{"commentary":1,"media":2}},"title":"Comparator criticism centers on evolving transplant/CAR-T eligibility and later treatment"},{"id":"F4","structure":{"claims":17,"claims_by_group":{"comparisons":3,"experience":2,"questions":3,"restated":4,"views":5},"has_counterview":true,"limitations":3,"links":{"context":2,"support":21},"ma_question":true,"named_voices":4,"passages":10,"sources":6,"sources_by_kind":{"commentary":2,"media":4}},"title":"Conditional preference for epcoritamab persists, while combinations and CAR-T positioning remain unsettled"},{"id":"F5","structure":{"claims":6,"claims_by_group":{"comparisons":2,"experience":0,"questions":0,"restated":0,"views":4},"has_counterview":true,"limitations":3,"links":{"context":0,"support":6},"ma_question":true,"named_voices":5,"passages":6,"sources":3,"sources_by_kind":{"commentary":3}},"title":"Cross-trial skepticism is qualified by regimen, line-of-therapy and histology differences"},{"id":"F6","structure":{"claims":13,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":10,"views":3},"has_counterview":false,"limitations":3,"links":{"context":0,"support":14},"ma_question":true,"named_voices":1,"passages":5,"sources":1,"sources_by_kind":{"media":1}},"title":"Off-the-shelf access requires a concrete monitoring and support model"},{"id":"F7","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":7,"views":4},"has_counterview":false,"limitations":4,"links":{"context":3,"support":12},"ma_question":true,"named_voices":3,"passages":6,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"Earlier use is supported by later-line activity and biological reasoning, not established by those premises"},{"id":"F8","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":3,"restated":0,"views":1},"has_counterview":false,"limitations":2,"links":{"context":0,"support":4},"ma_question":true,"named_voices":1,"passages":2,"sources":1,"sources_by_kind":{"media":1}},"title":"Sequencing, target reassessment, cure and long-term safety remain open"},{"id":"F9","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":6,"views":5},"has_counterview":true,"limitations":3,"links":{"context":0,"support":14},"ma_question":true,"named_voices":4,"passages":6,"sources":5,"sources_by_kind":{"commentary":5}},"title":"Confirmatory and regulatory implications are debated, not announced outcomes"},{"id":"F10","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":1,"views":3},"has_counterview":false,"limitations":3,"links":{"context":0,"support":6},"ma_question":false,"named_voices":5,"passages":5,"sources":5,"sources_by_kind":{"commentary":5}},"title":"Development feasibility and nonclinical reactions should remain separate from treatment evidence"}],"medical_affairs_question":"How should durable disease control be discussed alongside infection risk and the absence of a demonstrated survival advantage, while preserving the conditional choice over chemotherapy and the unresolved position relative to CAR-T?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Survival and infection risk constrain the interpretation of success"},{"id":"section-2","level":2,"title":"The perceived efficacy signal is response durability, not the median PFS difference"},{"id":"section-3","level":2,"title":"Comparator criticism centers on evolving transplant/CAR-T eligibility and later treatment"},{"id":"section-4","level":2,"title":"Conditional preference for epcoritamab persists, while combinations and CAR-T positioning remain unsettled"},{"id":"section-5","level":2,"title":"Cross-trial skepticism is qualified by regimen, line-of-therapy and histology differences"},{"id":"section-6","level":2,"title":"Off-the-shelf access requires a concrete monitoring and support model"},{"id":"section-7","level":2,"title":"Earlier use is supported by later-line activity and biological reasoning, not established by those premises"},{"id":"section-8","level":2,"title":"Sequencing, target reassessment, cure and long-term safety remain open"},{"id":"section-9","level":2,"title":"Confirmatory and regulatory implications are debated, not announced outcomes"},{"id":"section-10","level":2,"title":"Development feasibility and nonclinical reactions should remain separate from treatment evidence"},{"id":"section-11","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":23},{"id":"F2","shared_claims":2},{"id":"F9","shared_claims":4}],"id":"T1","label":"Primary endpoint: Overall Survival (OS)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":13},{"id":"F9","shared_claims":2}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":4},{"id":"F5","shared_claims":1},{"id":"F9","shared_claims":1}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F2","shared_claims":6},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":3},{"id":"F5","shared_claims":4},{"id":"F9","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":9},{"id":"F9","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F3","shared_claims":5},{"id":"F5","shared_claims":1},{"id":"F10","shared_claims":1}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-31T00:33:02.443174Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-31T00:48:32Z","record_hash":"61858bca5183e02416e5fa03cab96dc31a11638df1f10e71bd4a151315ddae0c","release_hash":"bbfa3502fda09cda1febcf229ec16dd7faa0528bebab33c0e24d5f9028b2f206","report_id":"erudio-nct04628494","run_id":"2d556720-fbf2-4b4f-abc9-d1248a0e2b02","schema_version":"5.0","slug":"epcore-dlbcl-1-04628494","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"EPCORE DLBCL-1 asks whether epcoritamab improves survival over chemotherapy in transplant-ineligible people whose diffuse large B-cell lymphoma has returned or resisted treatment. Commentary comes from X and LinkedIn posts, podcasts and YouTube, including a physician and a medical oncologist. The discussion turns on whether survival and infection findings support trial success, whether chemotherapy is an appropriate comparator and what remains unresolved for regulatory confirmation. The sources reviewed for this edition place its randomized phase 3 results at EHA 2026.","meta_description":"63 sources screened · 113 verified statements (39 from clinicians verified by NPI or staff page) from 19 sources · 10 findings. Updated Oct 31, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-88d39b517f762dbfc46f","claim-bad73edd5bb8f337714f"],"id":"F3","paraphrase":"A LinkedIn post asks how patients initially deemed unsuitable for transplantation could receive intensive treatment after progression.","source_channel":"linkedin_post","source_date":"2026-07-17","title":"Comparator criticism centers on evolving transplant/CAR-T eligibility and later treatment"},{"cited_claim_ids":["claim-115edc46e4e925f57b37"],"id":"F2","paraphrase":"A podcast discussion asks whether sustained control of lymphoma will translate into longer overall survival.","source_channel":"podcast","source_date":"2026-06-15","title":"The perceived efficacy signal is response durability, not the median PFS difference"}]},"publication":{"approved_at":"2026-10-31T00:48:32Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-10-31T02:18:15Z","summary":"Corrected to match the delivered report: the limitations; the sample findings; the report description."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":63},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some clinician views in the sources used in this report are not yet captured as evidence in this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","63 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition do not represent all HCP discussion. Remarks using unnamed references or less common variants may be missing, and several passages were not fully assessed for clinician views.","No results publication or full protocol for NCT04628494 was among the sources reviewed. Many numerical, endpoint and regulatory descriptions are commentary restatements or second-hand accounts.","The Pharma Closeout passages do not establish who delivered the words. Listed participants are not used to assign those views.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","The a podcast podcast and YouTube versions contain the same exchange; parallel versions and reposts do not constitute additional independent clinical views.","COVID-19, infection and subsequent-treatment explanations for OS remain interpretive. Unadjusted OS, COVID-19-censored curves and post hoc adjusted OS estimates are kept distinct.","Safety percentages differ in their descriptions and certainty: fatal adverse events are not necessarily treatment-related deaths, a speaker's 17% mortality denominator is unspecified, and the study associated with the Nordea safety paragraph is unclear.","The practical-care account is incomplete, particularly on first-full-dose setting, decisions during active infection, laboratory and immunoglobulin support, and assessment of new neurological symptoms. It should not be read as a complete treatment-delivery or treatment-holding framework.","Earlier single-arm studies and separate combination trials inform the treatment question but are not EPCORE DLBCL-1 results or head-to-head evidence against CAR-T.","FDA draft-guidance relays and proposed confirmatory implications are not treated as announced regulatory decisions.","Not yet captured in this edition: a view on bispecific-based treatment versus chemotherapy in transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma.","Not yet captured in this edition: a view on bispecific combinations versus chemotherapy in second-line transplant-ineligible relapsed or refractory DLBCL.","Not yet captured in this edition: a view on bispecific combination therapy versus chemotherapy in second-line relapsed or refractory diffuse large B-cell lymphoma.","Not yet captured in this edition: a remark on clarifying the epcoritamab combination partner while CAR-T eligibility remains uncertain.","Not yet captured in this edition: a view on distinguishing overall-population from second-line subgroup evidence when evaluating bispecific treatment in relapsed or refractory DLBCL.","Not yet captured in this edition: a view on efficacy, safety and regulatory qualifications of alternative bispecific-containing regimens in relapsed or refractory DLBCL.","Not yet captured in this edition: a remark on the combination partner and cellular-therapy eligibility in a related second-line epcoritamab comparison."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":1,"other":0,"podcast":3,"publication":0,"registry":0,"regulatory":0,"x_thread":14,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":19},"count":19,"evidence_window":{"end":"2026-10-06","start":"2020-12-10"},"retrieval_snapshot":"2026-10-30T23:31:10.985135Z","timeline":[{"count":1,"week":"2020-W50"},{"count":1,"week":"2025-W09"},{"count":1,"week":"2026-W03"},{"count":3,"week":"2026-W04"},{"count":1,"week":"2026-W21"},{"count":1,"week":"2026-W24"},{"count":3,"week":"2026-W25"},{"count":1,"week":"2026-W29"},{"count":4,"week":"2026-W30"},{"count":1,"week":"2026-W37"},{"count":1,"week":"2026-W38"},{"count":2,"week":"2026-W41"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT04628494:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04628494:context","quote_policy":"short_quote_link_out"},{"id":"openfda:d7836711-b677-412d-bf2d-0f7c8444103a:20260622","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-37ke4hieqksucnwp4a3htxwj-3mcrdfbq7zt2u","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-7eeegxgy3hkpipqnlzr7na4c-3mckqxtnl5n2t","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-b6or56vkmhywvtt2wkcsnbsc-3mo7ae7hya22n","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-b6or56vkmhywvtt2wkcsnbsc-3mrflhyowls2g","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-hslirr7h6d7livppaxty435b-3mckqzruu7o2o","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-jxznj5ix2wdnpgaokawrpt4n-3mcrgsifp572o","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-o6ggjvnj4ze3mnrpnv5oravg-3mcs5jpjnra2w","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-v2bbfxjs2fopw6y76ibai2cd-3msd6gknswj26","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7483883274096791552","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:5578cd","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:8bc9d5","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:f5ff8b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1327555869073174528:5c8c2540-1100-44da-8b7a-e4da6ac94c7a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1336999842317541378:4379b36f-f19a-4dc0-bb9c-8db4d02df3d7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1387420823221309446:fd317b8a-2915-43a8-b642-8dc0fd6b2db4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1402725514675109891:55580c68-fb19-45a8-b475-745a5915877c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1488286028452581384:81760537-9856-4348-8003-2be3f95f23d5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1506752688683376653:ad85de89-af24-42b0-83b2-aad2717ca174","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1508551437256642568:5b9b2bb4-7a3f-407c-a366-bde3f5e8b7b8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1516189897022976000:4188406c-d066-4e74-a933-7a38fd7d57dd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1609661954896891904:6d270e44-9bac-4f95-a87e-383394d9e333","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1624131108538355715:76452418-de28-4768-9b8e-966fe60cb285","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1626748433968074753:5ea5b1bf-6858-4826-9a56-882fbd508da1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1627382626477645824:da9422cd-d4a7-4588-b2a0-64ea0f6c47ed","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1801275325394874674:7164002d-c47c-4097-a699-aacbb55926fd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1895108120244035648:27836730-197e-4907-8482-4c73b0f00972","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2012231868746219625:dbeb1719-5ed0-4a98-851d-3380a7d7962a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2012233388908781740:2da2fc0d-44d5-480a-af2b-a86851eb1330","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2012276458761183301:c510d002-b280-4711-8c54-cd111b429e00","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2012282471895941321:fcf5246f-7e34-4422-9687-259e3f879863","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2012282712196006252:26f9ad0d-e755-473b-a15a-3aa2d64229ef","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2012365892751908928:bfdf63c3-0ac0-4230-a600-0042e898079b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2012366975154933983:4cdfccd1-97dd-4c4d-a163-93f924b9c9f5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2012564150245794259:f514f4a8-baed-47a7-b647-f67a497a6f96","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2013184010055520670:9863a783-db50-4f51-917a-d492fb501a62","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2013341875508240703:11c8ef64-c750-403c-a56a-25b3bf87ee6c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2013574730918527445:65fd8e9b-3366-452d-beef-6c8ddb5a8e64","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2013715117389533334:0f657206-f686-4f0c-b698-9634249716ce","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2014082489871151283:4ce8abd7-57ee-419d-96b3-3793ebcb84bd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2014420301191479714:0bf44df5-17a7-4b46-9458-67c894315cc8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2021343589079363798:6e19b44b-8769-4936-8a2a-27af3b933db1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2024542144044888419:10d52093-b470-4625-8f5a-b6cac8d51c13","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2058533808584933841:721c0064-86f1-420e-9369-53cf2c1bbb0b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2063830349046493673:975d8d99-1ecc-4d75-ab0f-960de5948705","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2065914286178767294:0aa58ebb-fc25-4aa7-a634-91e3c7e94ca2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2065914632322081031:33edde1d-c308-43f6-aab8-60f6f7e1e22d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2066408896965599509:d23231a3-0864-4bf2-a87b-368d471db55c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2066408955257999504:0d0e2189-6555-42d6-9e22-624375f81267","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2067892580222636524:69291420-4898-4f25-a2ac-5342f5c83be7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2069680419981693298:9a060512-c4dc-4671-bc32-06084c3cbd84","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2080216871081582664:e9af326c-ef3b-444c-9f67-9264e6f69600","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2080440130725405128:223aec28-6954-4b9c-9149-033e5fcbfae3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2080553315717542132:4ce46131-e909-43eb-8546-29f96a9ddd0a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2080629143528779845:9af609eb-cf61-4701-ab32-ffe3dc79f0a4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2080652828947763241:984ba38e-ac7c-4bb4-9028-acd0a74fe922","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2080664300344033585:6bebe294-2f1e-495f-8b43-a9aee235f4ed","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2080947338525474963:52172e46-8ec4-4f07-b5a6-d1dfb0ea1edd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2086512836314825028:28d90671-a22f-4ba9-8d69-91d46a5b54b5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092039323361095903:01ebb4e3-2aa7-4114-ac62-5d1a7854863b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098499049636688036:962f9bbc-0d8a-442d-88de-0a6404d3f7f4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099715301680042293:02edfaf7-68a6-4b4f-a4c4-8fe2e87e8355","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107326292639027246:1f0e9a71-5d43-49c9-9622-d6356d81d761","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:qBBuqHVosCE","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":8,"linkedin_post":1,"other":0,"podcast":3,"publication":0,"registry":0,"regulatory":0,"x_thread":50,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":63},"count":63,"evidence_window":{"end":"2026-10-06","start":"2020-11-14"},"retrieval_snapshot":"2026-10-30T23:31:10.985135Z","timeline":[{"count":1,"week":"2020-W46"},{"count":1,"week":"2020-W50"},{"count":1,"week":"2021-W17"},{"count":1,"week":"2021-W22"},{"count":1,"week":"2021-W23"},{"count":1,"week":"2022-W05"},{"count":1,"week":"2022-W12"},{"count":1,"week":"2022-W13"},{"count":1,"week":"2022-W16"},{"count":1,"week":"2022-W52"},{"count":1,"week":"2023-W06"},{"count":2,"week":"2023-W07"},{"count":1,"week":"2024-W24"},{"count":1,"week":"2025-W09"},{"count":10,"week":"2026-W03"},{"count":9,"week":"2026-W04"},{"count":1,"week":"2026-W07"},{"count":1,"week":"2026-W08"},{"count":1,"week":"2026-W21"},{"count":4,"week":"2026-W24"},{"count":4,"week":"2026-W25"},{"count":1,"week":"2026-W26"},{"count":1,"week":"2026-W29"},{"count":11,"week":"2026-W30"},{"count":2,"week":"2026-W32"},{"count":1,"week":"2026-W35"},{"count":1,"week":"2026-W37"},{"count":1,"week":"2026-W38"},{"count":2,"week":"2026-W41"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: epcoritamab","status":"unmapped"},{"reason":"Unmapped registry intervention: investigator's choice chemotherapy","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Diffuse large B-cell lymphoma","slug":"diffuse-large-b-cell-lymphoma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"EPCORE DLBCL-1","aliases":["EPCORE DLBCL-1","A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)","A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)"],"brief_title":"A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)","collaborators":["AbbVie"],"conditions":["Diffuse Large B-cell Lymphoma"],"display_condition":"relapsed/refractory diffuse large B-cell lymphoma","display_interventions":[["epcoritamab"]],"enrollment":{"count":483,"type":"ACTUAL"},"interventions":[{"name":"Epcoritamab","synonyms":["GEN3013","DuoBody®-CD3xCD20","EPKINLY™"],"type":"BIOLOGICAL"},{"name":"Investigator's Choice Chemotherapy","synonyms":["BR or R-GemOx"],"type":"DRUG"}],"nct_id":"NCT04628494","official_title":"A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2025-10-13","type":"ACTUAL"},"primary_endpoints":[{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 5 years"}],"registered_date":{"date":"2020-11-13","type":"ACTUAL"},"registry_last_updated":"2026-05-22","registry_url":"https://clinicaltrials.gov/study/NCT04628494","short_name":"EPCORE DLBCL-1","short_name_basis":"registry_acronym","sponsor":"Genmab","start_date":{"date":"2021-01-13","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"GCT3013-05","type":"sponsor_study_id"},{"id":"2023-504830-23-00","type":"ctis"},{"id":"2020-003016-27","type":"eudract_number"},{"domain":"Japan Registry for Clinical Trials (jRCT)","id":"jRCT2021220017","type":"registry"},{"domain":"ChinaDrugTrials.org.cn","id":"CTR20221558","type":"registry"},{"domain":"Clinical Research Site - mytrial","id":"MOH_2021-01-18_009672","type":"registry"},{"domain":"CCMO (the Netherlands)","id":"NL75079.056.20","type":"registry"},{"domain":"IRAS ID; UK Research Summaries Database","id":"286972","type":"other"}],"study_type":"INTERVENTIONAL"}}}